View Older Stories View More Recent Stories

Jul 21, 2023 09:30AM CHMP Recommends Evrysdi® for Babies Under Two Months Old with Spinal Muscular Atrophy
Jul 20, 2023 08:00AM PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial Results
Jul 19, 2023 04:30PM PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics Prize
Jul 18, 2023 04:30PM PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 17, 2023 04:30PM PTC Therapeutics (PTCT) Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
Jul 17, 2023 04:30PM PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial Officer
Jul 11, 2023 12:00PM PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and Sepiapterin
Jun 29, 2023 04:31PM PTC Therapeutics (PTCT) Reports Results from MIT-E Clinical Trial of Vatiquinone
Jun 29, 2023 04:30PM PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated Seizures
Jun 21, 2023 07:01AM PTC Therapeutics (PTCT) Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients
Jun 21, 2023 07:00AM PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease Patients
Jun 2, 2023 08:00AM PTC Therapeutics to Participate at Upcoming Investor Conferences
May 23, 2023 04:08PM PTC Therapeutics (PTCT) Vatiquinone MOVE-FA Registration-Directed Trial Did Not Meet Its Primary Endpoint
May 23, 2023 04:07PM PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed Trial
May 23, 2023 04:06PM PTC Therapeutics (PTCT) Announces Strategic Pipeline Prioritization
May 23, 2023 04:05PM PTC Therapeutics Announces Strategic Pipeline Prioritization
May 17, 2023 07:02AM PTC Therapeutics (PTCT) Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
May 17, 2023 07:00AM PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
Apr 28, 2023 08:00AM PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Apr 27, 2023 04:01PM PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
Apr 13, 2023 08:00AM PTC Therapeutics to Host Conference Call to Discuss First Quarter 2023 Financial Results
Mar 28, 2023 08:00AM PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Mar 24, 2023 07:31AM PTC Therapeutics (PTCT) Announces CEO Resignation
Mar 24, 2023 07:30AM Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics
Feb 21, 2023 04:05PM PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Feb 21, 2023 08:00AM PTC Therapeutics to Participate at Upcoming Investor Conferences
Feb 7, 2023 04:30PM PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results
Feb 3, 2023 08:00AM PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation
Feb 2, 2023 04:30PM PTC Therapeutics to Participate at Upcoming Investor Conference
Jan 19, 2023 08:00AM NICE Recommends Reimbursement for Translarna™
Jan 17, 2023 08:00AM PTC Therapeutics Launches 9th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community
Jan 11, 2023 04:30PM PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jan 9, 2023 09:17AM PTC Therapeutics (PTCT) FY23 Revenue Guidance Tops Consensus
Jan 9, 2023 09:15AM PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 41st Annual J.P. Morgan Healthcare Conference
Jan 4, 2023 04:30PM PTC Therapeutics to Participate at 41st Annual J.P. Morgan Healthcare Conference
Dec 1, 2022 08:07AM PTC Therapeutics (PTCT) Announces Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy
Dec 1, 2022 08:00AM Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy
Oct 27, 2022 04:23PM PTC Therapeutics (PTCT) Announces Strategic Financing Collaboration with Blackstone with up to $1 Billion in Funding
Oct 27, 2022 04:03PM PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results 
Oct 27, 2022 04:01PM PTC Therapeutics Announces Strategic Financing Collaboration with Blackstone with up to $1 Billion in Funding
Oct 18, 2022 04:02PM PTC Therapeutics (PTCT) Provides Update on Ongoing PIVOT-HD Trial For PTC518
Oct 18, 2022 04:01PM PTC Provides Update on Ongoing Global PIVOT-HD Trial For PTC518
Oct 13, 2022 08:00AM PTC Therapeutics to Host Conference Call to Discuss Third Quarter 2022 Financial Results
Oct 11, 2022 08:00AM PTC Therapeutics to Present Clinical and Real-World Evidence on Translarna™ at the Annual Congress of the World Muscle Society
Sep 7, 2022 08:00AM PTC Therapeutics' 2022 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
Sep 1, 2022 08:00AM PTC Therapeutics to Participate at Upcoming Investor Conferences
Aug 4, 2022 04:01PM PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results
Jul 21, 2022 08:00AM PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2022 Financial Results
Jul 20, 2022 08:00AM Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency
Jun 20, 2022 04:00PM PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy
View More Recent Stories View Older Stories